ATRIAL NATRIURETIC FACTOR: FETAL BLOOD VOLUME REGULATION
心房钠尿因子:胎儿血容量调节
基本信息
- 批准号:2024640
- 负责人:
- 金额:$ 8.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1993
- 资助国家:美国
- 起止时间:1993-12-09 至 1998-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The broad objective of this proposal is to define the role of atrial
natriuretic peptide (ANF) in the regulation of fetal blood volume and
cardiac function in health and disease. The proposal is based on the
hypothesis that ANF modulates fetal cardiac function by directly and
rapidly decreasing blood volume through its effect on vascular permeation
of fluid and protein into the interstitial compartment. In this model,
the fetal cardiac atria operate as a sense organ that monitors cardiac
filling and responds with elaboration of ANF, a chemical signal that
regulates the balance of intra-and extra-vascular fluid volume, in order
to maintain the most advantageous relationship between cardiac filling
and cardiac output. ANF may play a fundamental role in orchestrating the
critical relationship between ventricular stroke volume, cardiac growth,
and hemodynamic stability. ANF levels are routinely found to be
extremely high in infants dying from fetal hydrops. Among the infants
born with hydrops 50 to 98% do not survive. Work form our laboratory has
determined that ANF increases fluid and protein permeation in fetal
tissues. The finding that ANF is central in the pathophysiology of fetal
hydrops would suggest a therapeutic use for our laboratory has determined
that ANF increases fluid and protein permeation in fetal tissues. The
finding that ANF is central in the pathophysiology of fetal hydrops would
suggest a therapeutic use for the recently discovered ANF receptor
antagonists HS-142-1.
The specific aims of this investigation are to: 1) Determine if ANF
concentrations in the physiologic range cause decreases in fetal blood
volume and modulate cardiac function. 2) Determine if decreased fetal ANF
circulating concentrations and ANF receptor blockage cause increased
blood volume, and ventricular stroke volume by decreasing vascular
permeation of water and albumin. 3) Determine if chronic administration
of ANF produces hydrops fetalis and if ANF receptor blockade prevents
edema formation in a sheep model of chronic fetal anemia induced hydrops.
To accomplish these aims in the chronically instrumented near term fetal
lamb: a) ANF will be infused to produce increments of circulating hormone
within the range found during saline volume loading. b) Bilateral atrial
appendage ligation will be performed, the ANF receptor antagonist HS-142-
1 administered and vascular permeation of albumin in response to volume
expansion will be measured and, c) Intravascular and interstitial fluid
volume will be measured before and during a five day chronic
administration of ANF to the fetus and the ANF receptor antagonist HS-
142-1 will be administered to fetuses made hydropic by chronic isovolumic
hemorrhage. These specific aims integrate the long term commitment to
understanding the role of ANF in fetal and newborn fluid physiology with
a laboratory possessing expertise in fetal hemodynamics and ventricular
function.
该提案的主要目标是定义心房肌的作用,
利钠肽(ANF)在调节胎儿血容量和
健康和疾病中的心脏功能。 所涉提议主要是
心钠素通过直接和间接调节胎儿心功能假说
通过对血管渗透的影响迅速减少血容量
大量的液体和蛋白质进入组织间室。 在该模型中,
胎儿心房作为监测心脏感觉器官
填充并响应ANF的精心制作,一种化学信号,
调节血管内外液体量的平衡,
为了维持心脏充盈和心脏收缩之间的最有利关系,
和心输出量 胜利阵线可以在协调
心室每搏输出量,心脏生长,
和血液动力学稳定性。 ANF水平通常被发现是
婴儿死于胎儿水肿的几率极高 产下
出生时有积水的人有50 - 98%不能存活 我们实验室的工作形式
确定ANF增加胎儿的液体和蛋白质渗透,
组织中 ANF在胎儿病理生理学中的核心发现
我们的实验室已经确定
ANF增加胎儿组织中的液体和蛋白质渗透。 的
发现ANF在胎儿水肿的病理生理学中起中心作用,
建议最近发现的ANF受体的治疗用途
拮抗剂HS-142 - 1。
本研究的具体目的是:1)确定ANF是否
生理范围内的浓度导致胎儿血液中
调节心脏功能。2)确定胎儿ANF是否降低
循环浓度和ANF受体阻断导致增加
血容量和心室每搏输出量,
水和白蛋白的渗透。3)确定长期给药是否
的ANF产生胎儿水肿,如果ANF受体阻断剂阻止
在慢性胎儿贫血诱导水肿的绵羊模型中的水肿形成。
为了实现这些目标,在长期仪器近足月胎儿
羔羊:a)将输注ANF以产生循环激素的增量
在生理盐水体积加载期间发现的范围内。 B)双侧心房
将进行附件结扎,ANF受体拮抗剂HS-142-
1次给药和白蛋白的血管渗透对体积的反应
将测量扩张,以及,c)血管内和间质液
将在5天慢性给药前和给药期间测量体积
给予胎儿ANF和ANF受体拮抗剂HS-
将142 - 1给予通过慢性等容给药使胎儿水肿的胎儿。
出血 这些具体目标整合了长期承诺,
了解心钠素在胎儿和新生儿体液生理学中的作用,
一个拥有胎儿血流动力学和心室动力学专业知识的实验室,
功能
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GARY MICHAEL SILBERBACH其他文献
GARY MICHAEL SILBERBACH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GARY MICHAEL SILBERBACH', 18)}}的其他基金
TRN Symposium 2016: Consensus Study Group Meeting for the Care of Girls and Women with Turner Syndrome
2016 年 TRN 研讨会:特纳综合症女孩和妇女护理共识研究小组会议
- 批准号:
9194835 - 财政年份:2016
- 资助金额:
$ 8.21万 - 项目类别:
Health and Wellness in Turner Syndrome in the 21st Century
21 世纪特纳综合症的健康与保健
- 批准号:
8652173 - 财政年份:2014
- 资助金额:
$ 8.21万 - 项目类别:
ATRIAL NATRIURETIC FACTOR--FETAL BLOOD VOLUME REGULATION
心房钠尿因子--胎儿血容量调节
- 批准号:
2194602 - 财政年份:1993
- 资助金额:
$ 8.21万 - 项目类别:
ATRIAL NATRIURETIC FACTOR--FETAL BLOOD VOLUME REGULATION
心房钠尿因子--胎儿血容量调节
- 批准号:
2194601 - 财政年份:1993
- 资助金额:
$ 8.21万 - 项目类别:
ATRIAL NATRIURETIC FACTOR--FETAL BLOOD VOLUME REGULATION
心房钠尿因子--胎儿血容量调节
- 批准号:
2194600 - 财政年份:1993
- 资助金额:
$ 8.21万 - 项目类别:
ATRIAL NATRIURETIC FACTOR: FETAL BLOOD VOLUME REGULATION
心房钠尿因子:胎儿血容量调节
- 批准号:
2402958 - 财政年份:1993
- 资助金额:
$ 8.21万 - 项目类别:
相似海外基金
Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study
心钠素和心脏代谢健康的调节:基因型引导的人类生理学研究
- 批准号:
10627996 - 财政年份:2022
- 资助金额:
$ 8.21万 - 项目类别:
Atrial Natriuretic Peptide and Regulation of Cardiometabolic Health: A Genotype-Guided Human Physiological Study
心钠素和心脏代谢健康的调节:基因型引导的人类生理学研究
- 批准号:
10419574 - 财政年份:2022
- 资助金额:
$ 8.21万 - 项目类别:
Mitochondria-mediated effects and therapeutic potential of Atrial Natriuretic Peptide in salt-sensitive hypertension
心房钠尿肽在盐敏感性高血压中的线粒体介导作用和治疗潜力
- 批准号:
10676800 - 财政年份:2020
- 资助金额:
$ 8.21万 - 项目类别:
Mitochondria-mediated effects and therapeutic potential of Atrial Natriuretic Peptide in salt-sensitive hypertension
心房钠尿肽在盐敏感性高血压中的线粒体介导作用和治疗潜力
- 批准号:
10442162 - 财政年份:2020
- 资助金额:
$ 8.21万 - 项目类别:
Mitochondria-Mediated Effects and Therapeutic Potential of Atrial Natriuretic Peptide in Salt-Sensitive Hypertension Diversity Supplement
盐敏感性高血压多样性补充剂中心房钠尿肽的线粒体介导作用和治疗潜力
- 批准号:
10337412 - 财政年份:2020
- 资助金额:
$ 8.21万 - 项目类别:
Mitochondria-mediated effects and therapeutic potential of Atrial Natriuretic Peptide in salt-sensitive hypertension
心房钠尿肽在盐敏感性高血压中的线粒体介导作用和治疗潜力
- 批准号:
10472035 - 财政年份:2020
- 资助金额:
$ 8.21万 - 项目类别:
Development of a high-precision diagnostic method for heart failure utilizing abnormal biosynthesis of beta-atrial natriuretic peptide in the failing heart
利用衰竭心脏中β-心房钠尿肽的异常生物合成开发心力衰竭的高精度诊断方法
- 批准号:
20K08414 - 财政年份:2020
- 资助金额:
$ 8.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Atrial natriuretic peptide induces peroxisome proliferator
心钠素诱导过氧化物酶体增殖
- 批准号:
15K10206 - 财政年份:2015
- 资助金额:
$ 8.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Atrial natriuretic peptide prevents cancer metastasis through vascular endothelial cells.
心房钠尿肽可防止癌症通过血管内皮细胞转移。
- 批准号:
26461393 - 财政年份:2014
- 资助金额:
$ 8.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel strategy for heart failure treatment with recombinant atrial natriuretic peptide-induced cardiac progenitor cells
重组心钠素诱导的心脏祖细胞治疗心力衰竭的新策略
- 批准号:
25461069 - 财政年份:2013
- 资助金额:
$ 8.21万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




